AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8881621
Drug: Propofol 3‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3‐5 mg kg‐1 h‐1 i.v.
Trial: 3884128
Drug: Doxorubicin (A)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (A) 60 mg/m2
Trial: 3884128
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 and cyclophosphamide 500 mg/m2 (CA)
Trial: 3884128
Drug: Doxorubicin (A)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (A) 60 mg/m2 and Doxorubicin 60 mg/m2 and cyclophosphamide 500 mg/m2 (CA)
Trial: 30198644
Drug: Inhaled desflurane
RxNorm normalized name: desflurane Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled desflurane
Trial: 25435604
Drug: Diabegon (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabegon (4 gm daily)
Trial: 23059927
Drug: ASA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA therapy suspended for seven days before tooth extraction
Trial: 23059927
Drug: ASA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA therapy continued without suspension
Trial: 10599711
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (GH) discontinued after 2 years
Trial: 1769866
Drug: Ems brine
RxNorm normalized name: brine shrimp extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ems brine inhalations (200 ml, 3 times a day for 10 days)
Trial: 1769866
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (200 ml, 3 times a day for 10 days)
Trial: 6155131
Drug: Pseudoephedrine 180
RxNorm normalized name: fexofenadine-pseudoephedrine 180 mg-240 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 180 mg
Trial: 31335881
Drug: TNF inhibitor
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitor alone (n = 25)
Trial: 31335881
Drug: TNF inhibitor
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitor combined with methotrexate (MTX) (n = 10)
Trial: 31335881
Drug: MTX monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX monotherapy (n = 16)
Trial: 11234182
Drug: Weekly home
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly home fructosamine monitoring in addition to daily glucose monitoring
Trial: 11234182
Drug: Daily glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily glucose monitoring only (Control)
Trial: 15034317
Drug: UDCA (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (600 mg/day for 12 months)
Trial: 3706881
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered aminophylline (17.0 to 22.4 mg/L)
Trial: 3706881
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered aminophylline plus inhaled isoproterenol
Trial: 3706881
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered placebo
Trial: 15918560
Drug: Chemotherapy and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and/or radiotherapy
Trial: 11909787
Drug: Optimised insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimised insulin injections
Trial: 12377361
Drug: Four-session guided
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-session guided self-change treatment
Trial: 12377361
Drug: One-session advice
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-session advice treatment
Trial: 9846012
Drug: Response-oriented individualized
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response-oriented individualized induction therapy with six drugs (doxorubicin, mitoxantrone, vincristine, prednisolone, cyclophosphamide, L-asparaginase)
Trial: 9846012
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with leukocytes < 30,000/microliter and blasts < 10% on day 15
Trial: 7854594
Drug: 0.5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml/kg ethanol
Trial: 2509264
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment (sodium valproate or phenobarbitone)
Trial: 807007
Drug: Parenteral 1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral 1.75 per cent L‐essential amino acids in 47 per cent dextrose (Group I)
Trial: 28318451
Drug: Bacterial lysate
RxNorm normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial lysate administered 10 days per month for 3 months
Trial: 16485883
Drug: 3% diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% diclofenac sodium gel used for 90 days
Trial: 16485883
Drug: 5% 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% 5-fluorouracil cream used for 28 days
Trial: 15344544
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment (methods include Endoluminal Gastroplication, Full Thickness Plicator, Stretta, Enteryx, Gatekeeper)
Trial: 15344544
Drug: Medication and
RxNorm normalized name: CVS Health Medication and Topical Refill Pouch KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication and laparoscopic antireflux surgery
Trial: 10645920
Drug: High antibody
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High antibody levels to herpes simplex type I (HSV‐1)
Trial: 10645920
Drug: High antibody
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High antibody levels to Chlamydia pneumoniae (Cpn)
Trial: 10645920
Drug: Joint effect
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint effect of high antibody levels to HSV‐1 and Cpn
Trial: 10645920
Drug: Low antibody
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low antibody levels and low CRP
Trial: 1606999
Drug: Amitriptyline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (50 mg and 100 mg)
Trial: 8436156
Drug: Amoxapine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxapine (100 mg and 200 mg)
Trial: 30699060
Drug: Pazufloxacin 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazufloxacin 0.6% ophthalmic solution (BID, n = 90)
Trial: 30699060
Drug: Pazufloxacin 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazufloxacin 0.6% ophthalmic solution (TID, n = 76)
Trial: 30699060
Drug: Pazufloxacin 0.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazufloxacin 0.6% ophthalmic solution (QID, n = 68)
Trial: 23391599
Drug: Prophylactic paracetamol
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic paracetamol (PP) group
Trial: 23391599
Drug: Non-prophylactic paracetamol
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-prophylactic paracetamol (NPP) group
Trial: 17477886
Drug: Agomelatine 25
RxNorm normalized name: Agomelatine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 25 mg/d for 42 days
Trial: 14977803
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg p.o. preoperatively followed by placebo
Trial: 14977803
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg p.o. (three doses)
Trial: 9786475
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of DW-116 (100, 200, 300, and 800 mg)
Trial: 9786475
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of DW-116 (300 mg for 7 days)
Trial: 9786475
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of DW-116 (400 mg for 7 days)
Trial: 9786475
Drug: Single and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple dosing of DW-116
Trial: 8147929
Drug: Intraarticular injections
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular injections of hyaluronan (2.5 ml, weekly for 5 weeks)
Trial: 31664765
Drug: Cariprazine 4.5
RxNorm normalized name: cariprazine 4.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 4.5 mg/day
Trial: 31664765
Drug: Cariprazine (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine (dose range 1.5-6 mg/day for schizophrenia and 3-6 mg/day for bipolar mania)
Trial: 31664765
Drug: Cariprazine (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine (dose increase)
Trial: 18617483
Drug: Baseline NT-pro-BNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline NT-pro-BNP ≥ 9252 pg/mL (fourth quartile)
Trial: 11531681
Drug: ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4 mg (2 mg.ml‐1 solution) diluted into a 5‐ml solution
Trial: 11531681
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg lidocaine (5 ml 1% solution)
Trial: 11531681
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml of intravenous 0.9% sodium chloride solution (placebo)
Trial: 3155379
Drug: Vaccinia melanoma
RxNorm normalized name: vaccinia virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinia melanoma oncolysate (VMO) at higher doses (1.5 and 2.0 mg) with immediate treatment schedule
Trial: 3155379
Drug: Vaccinia melanoma
RxNorm normalized name: vaccinia virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinia melanoma oncolysate (VMO) with delayed treatment schedule
Trial: 3155379
Drug: Anti-HLA antibody
RxNorm normalized name: Anti-HLA antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-HLA antibody and circulating immune complexes
Trial: 31774306
Drug: Intragastric quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intragastric quinine 600 mg (Q600)
Trial: 31774306
Drug: Intragastric quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intragastric quinine 275 mg (Q275)
Trial: 23435143
Drug: Dai-kenchu-to (DKT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dai-kenchu-to (DKT) 2.5 g administered orally three times a day from postoperative day (POD) 1
Trial: 19812935
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate infusion (n = 6)
Trial: 19812935
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (n = 6)
Trial: 12554899
Drug: Pigtail drainage
RxNorm normalized name: PLEURX DRAINAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pigtail drainage combined with anti-TB drug treatment
Trial: 12554899
Drug: Only anti-TB
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only anti-TB drugs
Trial: 11054390
Drug: Interferon-ribavirin combination
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Interferon-ribavirin combination therapy for 24 weeks
Trial: 11054390
Drug: Interferon-ribavirin combination
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Interferon-ribavirin combination therapy for 48 weeks
Trial: 1323324
Drug: ACTH (1
RxNorm normalized name: SNP-ACTH (1-39)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH (1 mg i.m. in long-acting form)
Trial: 31841498
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg daily vitamin D supplementation
Trial: 31841498
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg daily vitamin D supplementation
Trial: 29883188
Drug: Standard analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard analgesic care (Control)
Trial: 26519116
Drug: Bi-weekly rotation
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bi-weekly rotation exercise classes (n=20)
Trial: 20199846
Drug: Goal-setting strategy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goal-setting strategy (mental contrasting), cognitive behavioral therapy-oriented problem-solving approach, goal-pursuit strategy (implementation intentions)
Trial: 18018417
Drug: Switch therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch therapy (injectable quinolone switched to oral quinolone)
Trial: 18018417
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of carbapenem antibacterial agent
Trial: 16287366
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (CM; 0.3 g.kg(‐1).day(‐1) + 20 g Polycose)
Trial: 10444418
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (0.25, 0.50, and 1 mU.kg(‐1).min(‐1)) in healthy controls
Trial: 10444418
Drug: Insulin deprivation
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin deprivation or insulin replacement in type 1 diabetic subjects
Trial: 7816064
Drug: Methotrexate (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (25 mg once weekly)
Trial: 31149870
Drug: AS03-adjuvanted multicomponent
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted multicomponent vaccine (CPS5/CPS8/α-toxin/ClfA)
Trial: 31149870
Drug: Non-adjuvanted multicomponent
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted multicomponent vaccine (CPS5/CPS8/α-toxin/ClfA)
Trial: 26813473
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus trimetazidine hydrochloride for 6 months
Trial: 24171895
Drug: Acupuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture with NSAIDs (zaltoprofen, 80 mg daily)
Trial: 12233877
Drug: Anti-TNF-α therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-α therapy
Trial: 19188654
Drug: Oral Syringe
RxNorm normalized name: Oral Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Syringe
Trial: 12492742
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lanzoprazole 30 mg, clarithromycin OD 500 mg, and furazolidone 400 mg, once daily for 7 days (Group A)
Trial: 12492742
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lanzoprazole 30 mg, clarithromycin OD 500 mg, and furazolidone 200 mg, once daily for 7 days (Group B)
Trial: 10831005
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 20 mg
Trial: 9433370
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 60 mg
Trial: 10831005
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 240 mg
Trial: 23428652
Drug: Multidisciplinary weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Multidisciplinary weekly family‐based behavioral group delivered via telemedicine
Trial: 18420096
Drug: CoStar drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoStar drug-eluting stent (DES)
Trial: 18420096
Drug: Taxus drug-eluting
RxNorm normalized name: Taxus baccata fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxus drug-eluting stent (DES)
Trial: 13129448
Drug: Beta-cryptoxanthin esters
RxNorm normalized name: lutein esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-cryptoxanthin esters from papaya (1.3 mg)
Trial: 13129448
Drug: Non-esterified beta-cryptoxanthin
RxNorm normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-esterified beta-cryptoxanthin (1.3 mg)
Trial: 10815894
Drug: Antivascular endothelial
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antivascular endothelial growth factor antibodies
Trial: 9028752
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indomethacin 100 mg
Trial: 9028752
Drug: Intravenous pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pethidine alone
Trial: 1667648
Drug: Dietary fibre
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fibre supplementation (wheat fibre and ispaghula) at an average intake of 16 g per day for six months
Trial: 6219156
Drug: Inhaled ipratropium
RxNorm normalized name: ipratropium Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ipratropium plus oral oxtriphylline
Trial: 6219156
Drug: Inhaled fenoterol
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fenoterol plus oral oxtriphylline
Trial: 6219156
Drug: Inhaled ipratropium
RxNorm normalized name: ipratropium Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ipratropium and fenoterol plus oral oxtriphylline
Trial: 26637166
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (2 mg) administered as 3 monthly loading doses, followed by injections every 2 months over 12 months
Trial: 24388619
Drug: Chlorthalidone-based stepped-care
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone-based stepped-care therapy
Trial: 23017669
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (three cycles of OxMdG: oxaliplatin 85 mg/m², l‐folinic acid 175 mg, fluorouracil 400 mg/m² bolus, then 2400 mg/m² by 46 h infusion) followed by surgery and a further nine cycles of OxMdG
Trial: 23017669
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy (12 cycles of OxMdG)
Trial: 15288712
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (human regular insulin 4 x 40 IU/d)
Trial: 9310280
Drug: Almokalant at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almokalant at 100 nmol/l
Trial: 9310280
Drug: Almokalant at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almokalant at 50 nmol/l
Trial: 9310280
Drug: Almokalant at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almokalant at 20 nmol/l
Trial: 9310280
Drug: Almokalant at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almokalant at 150 nmol/l
Trial: 28937221
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg tablet) under fasting conditions
Trial: 28937221
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg tablet) under fed conditions
Trial: 28937221
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg tablet)
Trial: 25982133
Drug: Subanaesthetic ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanaesthetic ketamine (0.29 mg kg(‐1) h(‐1) for 1 h, followed by 0.57 mg kg(‐1) h(‐1) for another hour)
Trial: 23813743
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg 4-aminopyridine (4-AP) four times a day for 3 days
Trial: 23813743
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg 4-aminopyridine (4-AP) four times a day for 4 days
Trial: 21541781
Drug: Macitentan 600
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan 600 mg